Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00324506
Recruitment Status : Completed
First Posted : May 11, 2006
Last Update Posted : June 19, 2013
Sponsor:
Collaborator:
Aspreva Pharmaceuticals
Information provided by (Responsible Party):
Elliot Frohman, University of Texas Southwestern Medical Center

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : June 2009
Actual Study Completion Date : June 2009
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 October 15, 2013
December 11, 2013